Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 4Recruiting 2Completed 2

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 2Thoracic 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Oligometastatic Prostate Cancer 1Colorectal Neoplasms 1Cholangiocarcinoma 1Bile Duct Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
quemliclustat × Clear all
NCT06608927 2026-05-08

PRISM-1

Arcus Biosciences, Inc.

Phase 3 Active not recruiting
610 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04104672 2026-05-07

ARC-8

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
196 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-04-29

EDGE-Gastric

Arcus Biosciences, Inc.

Phase 2 Active not recruiting
332 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05676931 2025-10-02

EDGE-Lung

Gilead Sciences

Phase 2 Active not recruiting
400 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05915442 2025-05-20

SBRT-AMICO

Columbia University

Phase 2 Recruiting
23 enrolled
Genitourinary

Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡